Kancera AB
http://kancera.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kancera AB
Kancera’s Fractaline Blockers May Fight Ovarian Cancer
Kancera AB’s fractalkine blockers have the potential to stop cancer cells acquiring resistance to chemotherapy and so offer potential to improve treatment for some advanced cancers, the Swedish biotech’s CEO tells Scrip.
Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice